Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-101 with Docetaxel and Prednisone in HRPC
NCT00286793Phase 2Completed
- Sponsor
- Ascenta Therapeutics
- Start
- Feb 2006
- Primary completion
- Nov 2009
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of r-(-)-gossypol acetic acid in prostate cancer (PCa), sponsored by Ascenta Therapeutics. Primary endpoint: Safety of AT-101 in combination with docetaxel and prednisone at 12 months. Started Feb 2006; status: completed.
02
Drugs
r-(-)-gossypol acetic acid
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00286793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00286793.